Bart Barlogie, M.D., Ph.D.
Professor of Medicine and Pathology

Tommy May Chair in Oncology
Director, Myeloma Institute

M.D. Heidelberg University, University of Munich
Ph.D. Max Planck Institute for Medical Research
Residency (internal medicine, hematology and infectious diseases, rheumatology, nephrology, cardiology, gastroenterology), University of Muenster.
Clinical Fellowship(oncology), M.D. Anderson Hospital and Tumor Institute.

Numerous Professional Appointments at M.D. Anderson, including:

• Professor of Medicine, Department of Hematology

• Professor of Pathology, Department of Pathology

• Chief, Section of Experimental Therapeutics, Department of Hematology

• Chief, Cytometry Center, Department of Hematology ology

Honors and Awards:

• Distinguished Alumnus Award – UT MD Anderson Cancer Center – 1998
• Jan Waldenstrom Award for Myeloma Research – 1999
• Celgene Career Achievement Award in Hematology Research – 2002
• Robert A. Kyle Lifetime Achievement Award,
  International Myeloma Foundation – 2004
• National Physician of the Year Award for Clinical Excellence,
  Castle Connolly Medical Ltd., 2006

Society Memberships:

• American Society for Clinical Investigation

• American Society of Clinical Oncology

• American Society of Hematology

• Association of American Physicians

• International Society of Hematology

• The American Society for Bone and Mineral Research

Selected Publications:

Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents.  N. Engl. J. Med. 1984, 310(21):1353-1356.

Barlogie B, Alexanian R, Dixon D, Smith L, Smallwood L, Delasalle K: Prognostic implications of tumor cell DNA and RNA content in multiple myeloma. Blood 1985, 66(2):338-341.

Barlogie B, Alexanian R, Pershouse M, Smallwood L, Smith L:  Cytoplasmic immunoglobulin content in multiple myeloma. J. Clin. Invest. 1985, 76:765-769.

Barlogie B, Hall R, Zander A, Dicke K, Alexanian R: High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986, 67(5):1298-1301.

Alexanian R, Barlogie B, Dixon D: High dose glucocorticoid treatment of resistant myeloma. Ann. Int. Med. 1986, 105(1):8-11.

Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S, Horowitz L: High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma.  Blood 1987, 70(3):869-872.

Tsuchiya H, Epstein J, Selvanayagam P, Dedman JR, Gallick G, Alexanian R, Barlogie B: Correlated flow cytometric analysis of H-ras p21 and nuclear DNA in multiple myeloma. Blood 1988, 72(2):796-800.

Gould J, Alexanian R, Goodacre A, Pathak S, Hecht B, Barlogie B: Plasma cell karyotype in multiple myeloma. Blood 1988, 71(2):453-456.

Selvanayagam P, Blick M, Narni F, van Tuinen P, Ledbetter DH, Alexanian R, Saunders G, Barlogie B: Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma.  Blood 1988, 71(1):30-35.

Barlogie B, Alexanian R, Smallwood L, Cheson B, Dixon D, Dicke K, Cabannilas F: Prognostic factors with high-dose melphalan for refractory multiple myeloma. Blood 1988, 72(6):2015-2019.

Barlogie B, Epstein J, Selvanayagam P, Alexanian R: Plasma cell myeloma - new biologic insights and advances in therapy.  Blood 1989, 73(4):865-879.

Barlogie B, Smallwood L, Smith T, Alexanian R: High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann. Int. Med. 1989, 110(7):521-525.

Barlogie B, Velasquez WS, Alexanian R, Cabanillas F:  Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma. J. Clin. Oncol. 1989, 7(10):1514-1517.

Barlogie B, Jagannath S, Dixon DO, Cheson B, Smallwood L, Hendrickson A, Purvis JD, Bonnem E, Alexanian R: High-dose melphalan and GM-CSF for refractory multiple myeloma. Blood 1990, 76(4): 677-680.

Jagannath S, Barlogie B, Dicke K, Alexanian R, Zagars G, Cheson B, LeMaistre FC, Smallwood L, Pruitt K, Dixon DO: Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood 1990, 76(9):1860-1866.

Dimopoulos MA, Barlogie B, Smith TL, Alexanian R: High serum lactic dehydrogenase as a marker of drug resistance in multiple myeloma. Ann. Int. Med. 1991, 115(12):931-935.

Barlogie B: Toward a cure for multiple myeloma? NEJM 1991, 325(18):1304-1306.

Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B: Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992, 80(7):1666-1672.

Barlogie B, Alexanian R, Jagannath S: Plasma cell dyscrasias.  J. Am. Med. Assoc. 1992,  268(20):2946-2951.

Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B: Primary dexamethasone treatment of multiple myeloma. Blood 1992, 80(4):887-890.

Barlogie B, Vesole DH, Jagannath S: Salvage therapy for multiple myeloma:  The University of Arkansas experience.   Mayo Clin Proc 1994, 69:787-795.

Dao DD, Sawyer JR, Epstein J, Hoover RG, Tricot G and Barlogie B:  Deletion of the retinoblastoma gene on multiple myeloma.  Leukemia 1994, 8(8):1280-1284.

Beck JT, Hsu Su-Ming, Wijdenes J, Bataille R, Klein B, Vesole DH, Hayden K, Jagannath S, Barlogie B: Alleviation of systemic manifestations of castleman's disease by monoclonal anti-IL-6 antibody therapy. NEJM 1994, 330(9):602-605.

Vesole DH, Barlogie B, Jagannath S, Crowley J, Cheson B and Tricot G:  High dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants.  Blood 1994, 84(3):950-956.

Salmon S, Crowley J, Grogan T, Finley P, Pugh R and Barlogie B:  Combination Chemotherapy, Glucocorticoids and Interferon Alpha in the Treatment of Multiple Myeloma.  A Southwest Oncology Group Study.  JCO 1994, 12(11):2405-2414.

Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H and Epstein J:  Interleukin-6 prevents dexamethasone-induced myeloma cell death.  Blood 1995, 11:3063-3070.

Tricot G, Jagannath S, Vesole DH, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, and Barlogie B:  Peripheral Blood Stem Cell Transplants for Multiple Myeloma -Identification of Favorable Variables for Rapid Engraftment in 225 Patients.  Blood 1995, 85(2):588-596.

Sawyer J, Waldron J, Jagannath S and Barlogie B:  Cytogenetics Findings in 200 Patients With Multiple Myeloma.  Cancer Genetics and Cytogenetics 1995, 82:41-49.

Barlogie B, Jagannath S, Vesole DH, Tricot G:  Autologous and Allogeneic transplants for multiple myeloma.  Sem. in Hematol. 1995, 32(1) 31-44. 

Bataille R, Barlogie B, Lu Z, Rossi JF, Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B: Biologic Effects of Anti-Interleukin-6 (IL-6) Murine Monoclonal Antibody in Advanced Multiple Myeloma.  Blood 1995, 86(2) 685-691.

Tricot G, Sawyer J, Jagannath S, Bracy D, Mattox S, Vesole D, Naucke S, Barlogie B: Poor Prognosis in Multiple Myeloma is Associated Only with Partial or Complete Deletions of Chromosome 13 or Abnormalities Involving 11q and Not with Other Karyotype Abnormalities. Blood 1995, 86(11):4250-4256.

Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N and Barlogie B : Graft-Versus-Myeloma Effect:  Proof of Principle. Blood 1996, 87(3) 1196-1198.

Tricot G, Alberts DS, Johnson CS, Roe DJ, Dorr RT, Vesole DH, Jagannath S, Meyers R, Barlogie B: Safety of Autotransplants with High Dose Melphalan in Renal Failure:  A Pharmacokinetic and Toxicity Study. Clin. Can. Rsch. 1996, 6(2):947-952.

Govindarajan R, Jagannath S, Flick J, Vesole D, Sawyer J, Barlogie B and Tricot G:  Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br. J. Haematol. 1996, 95:349-353 .

Barlogie B, Jagannath S, Vesole D, Tricot G, Naucke S, Cheson B, Mattox S, Bracy D,  Salmon S, Jacobson J and Crowley J:  Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.  Blood 89:789-793, 1997 .

Dhodapkar M, Jagannath S, Vesole DH, Munshi N, Naucke S, Tricot G and Barlogie B:  Treatment of AL-amyloidosis with dexamethasone plus alpha interferon.  Leukemia/Lymphoma, 27:351-356, 1997.

Tricot G, Sawyer J, Jagannath S, Desikan KR, Siegel D, Naucke S, Mattox S, Bracy D, Munshi N and Barlogie B:  The unique role of cytogenetics in the prognosis of patients with myeloma receiving high dose therapy and autotransplants.  JCO, 15:2659-2666, 1997.

Barlogie B:  Advances in therapy of multiple myeloma: lessons from acute leukemia.  Clincal Cancer Research 3:2605-2613, 1997.

Dhodapkar M, Kelly T, Theus A, Athota A, Barlogie B, Sanderson R:  Elevated levels of shed syndecan-1 correlate with tumor mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma.  Br J Hem 99:368-371, 1997.

Jagannath S, Vesole DH, Zhang M, Desikan KR, Copeland N, Jagannath M, Bracy D, Jones R, Crowley J, Tricot G and Barlogie B:  Feasibility and cost effectiveness of outpatient autotransplants in multiple myeloma.  BMT 20:445-450, 1997.

Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Alexanian R, Crowley J, and Tricot G:  Long term follow-up after high dose therapy for high risk multiple myeloma. BMT 21(11):1101-1107, 1998.

Zent CS, Wilson CS, Tricot G, Jagannath S, Siegel S, Desikan KR, Munshi N, Bracy D, Barlogie B, and Butch AW:  Oligoclonal protein bands and immunoglobulin isotype switching in multiple myeloma patients treated with autologous bone marrow transplantation. Blood 91(9):3518-3523, 1998.

Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A, Munshi N, Singhal S, Mehta J, Tindle S, Nelson J, Bracy D, Mattox S, and Tricot G:  Comparable engraftment kinetics following peripheral blood stem cell infusion mobilized with G-CSF with or without cyclophosphamide in multiple myeloma.  JCO 16(4):1547-1553, 1998.

Dhodapkar M, Singh J, Mehta J, Fassas A, Desikan K, Perlman M, Munshi N, and Barlogie B:  Anti-myeloma activity of pamidronate in vivo.  Br J Hem 103(2):530-532, 1998.

Dhodapkar M, Abe E, Theus A, lacy M, Langford K, Barlogie B and Sanderson R:  Syndecan-1 is a multifunctional regulator of myeloma pathobiology:  Control of tumor cell survival, growth and bone cell differentiation.  Blood 91(8):2679-2688, 1998.

Dhodapkar MV, Weinstein R, Tricot G, Jagannath S, Parfitt AM, Manolagas SC, and Barlogie B:   Biologic and therapeutic determinants of bone mineral density in multiple myeloma.  Leukemia and Lymphoma 32(1-2):121-127, 1998.

Yaccoby S, Barlogie B, Epstein J:  Primary Myeloma Cells Growing in SCID-hu Mice:  A Model For Studying the Biology and Treatment of Myeloma and its Manifestations.  Blood 92(8):2908-13, 1998.

Rudnicki S, Harik S, Dhodapkar M, Barlogie B, Eidelberg D:  Nervous System Disfunction in Waldenstrom’s Macroglobulinemia:  Response to chemotherapy and Autotransplant.  Neurology 32(1-2):121-127, 1998.

Sawyer J, Lukacs J, Munshi N, Desikan R, Singhal S, Mehta J, Siegel D, Shaughnessy J and Barlogie B:  Identification of New Nonrandom Translocations in Multiple Myeloma With Multicolor Spectral Karyotyping.  Blood 92(11):4269-4278, 1998.

Sawyer J, Tricot G, MattoxS, Jagannath J,and Barlogie B:  Jumping Translocations of Chromosome 1q in Multiple Myeloma:  Evidence for a Mechanism Involving Decondensation of Pericentromeric Heterochromatin.  Blood 91(5):1732-1741, 1998.

Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel S:  NF-ĸB plays a role in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2.  Blood 93(9):3044-52, 1999.

Siegel D, Desikan R, Mehta J, Singhal S, Fassas A, Munshi N, Anaissie E, Naucke S, Ayers D, Spoon D, Vesole D, Tricot G and Barlogie B:  Age is not a prognostic variable with autotransplants for multiple myeloma.  Blood 93(1):51-54, 1999.

Barlogie B, Jagannath S, Desikan R, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar M, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J:  Total Therapy with Tandem Transplants for Newly Diagnosed Multiple Myeloma.  Blood 93(1):55-65, 1999.

Singhal S, Mehta J, Desikan R, Siegel D, Anaissie E, Munshi N, Wilson C, Hough A, Zeldis J, Dhodapkar M, and Barlogie B: Antitumor Activity of Thalidomide in Refractory Multiple Myeloma. NEJM 341(21):1565-71, 1999.

Shaughnessy J, Tian E, Sawyer J, Bumm K, Landes R, Badros A, Morris C, Tricot G, J. Epstein and Barlogie B:  High Incidence of Chromosome 13 Deletions in Multiple Detected by Multiprobe Interphase FISH.  Blood 96:1505-1511, 2000.

Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi N, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P and Crowley J: Results of High Dose Therapy for 1,000 Patients with Multiple Myeloma: Durable Complete Remissions and Superior Survival in the Absence of Chromosome 13 Abnormalities.  Blood 95:4008-4010, 2000.

Desikan KR, Tricot G, Dhodapkar M, Fassas A, Siegel D, Vesole DH, Jagannath S, Singhal S, Nehta J, Spoon D, Anaissie E, Barlogie B and Munshi N: Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone.  BMT 25:483-487, 2000.

Desikan K.R., Tricot G., Munshi N.C., Anaissie E., Spoon D., Fassas A., Toor A., Zangari M., Badros A,. Morris C., Vesole D.H., Siegel D., Jagannath S., Barlogie B.  Preceding Chemotherapy, tumor load and age influence engraftment in Multiple Myeloma patients mobilized with granulocyte colony-stimulating factor alone. Br J of Hem 112:242-247, 2000.

Sawyer J, Lukacs J, Thomas E, Swanson C, Goosen L, Sammartino G, Gilliland J, Munshi N, Tricot G, Shaughnessy J, Barlogie B: Multicolor spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J of Hem 112:167-174, 2000.

Wilson C, Butch An, Lai R, Medeiros J, Sawyer J and Barlogie B: Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalieeis and DNA ploidy.  Br J Hem 112:776-782, 2001.

Badros A, Barlogie B, Morris C, Desikan R, Martin S, Munshi N, Zangari M, Toor A, Cottler-Fox M, Fassas A, Anaissie E, Schichman S, Tricot G: High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocupte infusions.  Blood 97(9):2574-2579, 2001.

Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal A, Morris C, Toor A, Siegel E, Fink L, Tricot G: Increased Risk of Deep Vein Thrombosis in Patients with Multiple Myeloma Receiving Thalidomide and Chemotherapy.  Blood 98:1614-1615, 2001.

Dhodapkar M, Joth J, Gertz M, Rivkin S, Roodman D, TuscanoJ, Shurafa M, Kyle R, Crowley J, Barlogie Bart: Prognostic Factors and Response to Fludarabine Therapy in Waldenstrom’s Macroglobulinemia: Results of US Intergroup Trial (SWOG S9003).  Blood 98(1):41-48, 2001.

Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari    M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G. Extended survival    in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 98(2):492-  494, 2001.

Badros A, Barlogie B, Siegel E, Morris C, Desikan R, Zangari M, Fassas A, Anaissie E,   Munshi N and Tricot G: Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J of Hem 114:1-9, 2001.

Shaughnessy J, Gabrea A, Yi Q, Brents L, Zhan F, Tian E, Sawyer J, Barlogie B, Bergsagel P.L. and Kuehl M. Cyclin D3 at 6p21 is dysregulated by recurrent chromosmal translocations to immunoglobulin loci in multiple myeloma. Blood 98(1):217-223, 2001.

Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, Desikan R, Shaver M, Fassas A, McConnell S, Muwalla F, Barri Y, Anaissie E, Munshi N and Tricot G. Results of autologous stem cell transplant in multiple myeloma patients with renal failure.  Br J Hem 114:822-829, 2001.

Gertz M, Lacy M, Dispenzieri A, Cheson B, Barloige B, Kyle R, Palladini G, Geyer S, Merlini G.  A multicenter phase II trial of 4’-iodo-4’-deoxydoxorubicin (IDOX) in primary amyloidosis (AL).  Amyloid 9(1):24-30, 2002.

Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, van Rhee F, Tricot G. Improved outcome of non-myeloablative allogeneic transplantation in multiple myeloma. J Clin Onc 20:1295-1303, 2002.

Badros A, Siegel E, Bodenner D, Zangari M, Zeldis J, Barloige B, Tricot G. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med 112:412-413, 2002.

Zhan F, Hardin J, Kordsmeier B, BummK, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fasas A, Crowley J, Tricot G, Barlogie B and Shaughnessy S. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance and normal bone marrow plasma cells.  Blood 99:1745-1757, 2002.

Yaccoby S, Pearse R, Johnson C, Barlogie B, Choi Y and Epstein J. Myeloma interacts with the bone marrow microenvironmnet to induce osteoclastogenesis and is dependent on osteoclast activity.  Br J Hem 116:278-290, 2002.

Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A, Badros A, Zangari M, Munshi N, Anaissie E, Toor A and Barlogie B.  Predicting long-term (> 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants.  Br J Hem 116:211-217, 2002.

Fassas A, Muwalla F, Berryman T, Benramdane R, Joseph L, Anaissie E, Sethi R, Desikan R, Siegel D, Badros A, Toor A, Zangari M, Morris C, Angtuaco E, Mathew S, Wilson C, Hough A, Harik S, Barlogie B and Tricot G.  Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations.  Br J Hem 117:103-108, 2002.

Badros A, Morris C, Zangari M, Barlogie B, Tricot G.  Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.  Leukemia and Lymphoma 43:1267-1271, 2002.

Fassas A, Muwalla F, Berryman T, Benramdane R, Jospeh L, Anaissie E, Sethi R, Desikan R, Siegel D, Badros A, Toor A, Zangari M, Morris C, Angtuaco E, Mathew S, Wilson C, Hough A, Harik S, Barlogie B and Tricot G. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedully manifestations. Br J Hem 117:103-108, 2002.

Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100:1168-1171.

Fassas A, Spencer T, Sawyer J, Zangari M, Lee C, Anaissie E, Muwalla F, Morris C, Barlogie B, Tricot G.  Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma.  Br J of Hem 2002; 118:1041-1047.

Fassas A, Spencer T, Desikan R, Zangari M, Anaissie E, Barlogie B and Tricot G.  Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients.  Br J Hem 119:164-168, 2002.

Barlogie B, Shaughnessy J, Zangari M, Tricot G. High-dose therapy and immunomodulatory drugs in multiple myeloma. Semin Oncol 2002; 29:26-33. 

Lee C, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, van Rhee F, Cottler-Fox M, Thertulien R, Muwalla F, Mazher S, Badros A, Tricot G. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant 2002; 30:873-878.

Shaughnessy J, Barlogie B. Integrating cytogenetics and gene expression profiling in the molecular analysis of multiple myeloma. Int J Hematol 2002; 76:59-64.

Barlogie B, Shaughnessy J. Early results of Total Therapy II in multiple myeloma: implications of cytogenetics and FISH. Int J Hematol 2002; 76:337-339.

Yaccoby S, Johnson C, Mahaffey S, Wezeman M, Barlogie B, Epstein J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood 2002; 100:4162-4168.

Munshi N, Tricot G, Desikan R, Badros A, Zangari M, Toor A, Morris C, Anaissie E, Barlogie B.  Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 2002; 16:1835-1837.

 Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100:1168-1171.

Zhan F, Tian E, Bumm K, Smith R, Barloige B, Shaughnessy J. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development.  Blood 2003; 101:1128-1140.

Shaughnessy J, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, Anaissie E, Zangari M, Fassas A, Muwalla F, Morris C, Barlogie B. Prognostic impact of cyotogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of Total Therapy II. Br J Hem 2003; 120:44-52.

Morris C, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A, Zangari M, Anaissie E, Tricot G. Mobilization of CD34+ cells in elderly patients (>/=70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Hem 2003; 120:413-423.

Wu K, Orme L, Shaughnessy J, Jacobson J, Barlogie B, Moore M. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status and overall survical.  Blood 2003; 101: 4982-1989.

Xie J, Wang Y, Freeman M, Barlogie B, Yi Q. Beta-2-microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells.  Blood 2003; 101: 4005-4012.

Shaughnessy J, Barlogie B, Sawyer J, McCoy J, Fassas A, Zhan F, Bumm K, Epstein J, Anaissie E, Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari M, Jacobson J, Crowley J, Tricot G. Continuous absence of metaphase-defined cytogenetic abnormalities especially of chromosome 13 and hypodiploidy assures long-term survival in multiple myeloma treated with Toal Therapy I; interpretation in the context of global gene expression.  Blood 2003; 101: 3849-3856.

Desikan R, Barlogie B, Sethi R, Toor A, Spoon D, Angtuaco E, Vanhemert R, VijayaGopal A, Singhal S, Mehta J, Jagannath S, Munshi N, Zangari M, Fassas A, Tricot G, Anaissie E. Infection – an underappreciated cause of bone pain in multiple myeloma. Br J Hem 2003; 120: 1047-1050.

Kyle R, Treon S, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M, Lister T, Merlini G, Morel P, Stone M, Branagan A, Leblond V. Prognostic markers and criteria to intitiate therapy in Waldenstrom’s Macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003; 30: 116-120.

Richardson P, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar S, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski R, Kuter D, Limentani S, Lee S, Hideshima T, Esseltine D, Kauffman M, Adams J, Schenkein D, Andreson K. A phase 2 study of bortezomib in relapsed, refractory myeloma. NEJM 2003; 348: 2609-2617.

Zhan F, Barlogie B, Shaughnessy J.  Toward the identification of distinct molecular and clinical entities of multiple myeloma using global gene expression profiling.  Semin Hematol 2003; 40: 308-320.

Fassas A, Barlogie B, Ward S, Jagannath S, Vesole D, Mattox S, Siegel D, Muwalla F, Zangari M, Anaissie E, Rhee F, Thertulien R, Lee CK, Desikan R, Arzumanian V, McCoy J, Tricot G.  Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas Total Therapy I experience.  Br J Haematol 2003; 123: 484-489.

Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy J.   The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.  NEJM 2003; 349: 2483-2494.

Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R, Crowley J.  Treatment of multiple myeloma.  Blood 2004; 103:20-32.